{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for medroxyprogesterone root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA022032
(2008)
Source URL:
First approved in 2006
Source:
ANDA218434
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2024)
Source:
NDA214511
(2024)
Source URL:
First approved in 2024
Source:
NDA214511
Source URL:
Class:
PROTEIN
Status:
Excipient
Class:
POLYMER
Status:
Excipient
Source:
9.2mg ORAL TABLET, EXTENDED RELEASE
Source URL:
Class:
POLYMER
